Stephen S. Chung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stephen S. Chung has a total of 259 co-authors. Here are the top co-authors by number of shared publications:
- Robert H. Collins
Department of Internal Medicine University of Texas Southwestern Medical Center 75390 Dallas TX USA
81 shared publications - Yazan F. Madanat
Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, USA
81 shared publications - Fatma Neslihan Kalkan
Department of Internal Medicine University of Texas Southwestern Medical Center 75390 Dallas TX USA
79 shared publications - Wenhuo Hu
Department of Pathology, Center of Excellence for Leukemia Studies, St. Jude Children’s Research Hospital, Memphis, TN (W.H.).
68 shared publications - Amer Methqal Zeidan
Hematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, CT
67 shared publications - Abeer Ahmedrabie
Division of Hematology/Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas
66 shared publications
Latest Publications
- Open Access
Persistent Malignant Stem Cells Drive Relapse After Transplantation in the Myelodysplastic Neoplasms
The myelodysplastic neoplasms (MDS) are initiated in hematopoietic stem cells (HSCs). Allogeneic transplantation is the only curative treatment, but relapse remains common. To detect rare MDS HSCs, we developed an ultra-low-input DNA sequencing assay and applied it to a multicenter post-transplant cohort. HSC mutation detection preceded relapse by a mean of 98 days and strongly predicted relapse (95.7% vs. 30.3%; hazard ratio, 8.8; P=1.5e-7). Mutations detected only in unfractionated marrow did not predict relapse. We developed methods to measure donor-host HSC chimerism, improving relapse prediction sensitivity. Single-cell protein, DNA, and RNA analyses with mitochondrial lineage tracing confirmed MDS cell enrichment within immunophenotypically- and transcriptionally-defined HSCs, identifying shared ribosomal gene downregulation and candidate mechanisms of venetoclax sensitivity. Venetoclax/azacytidine depleted detectable MDS HSCs in longitudinally evaluated patients. These findings establish that HSC mutation detection predicts post-transplant relapse, provide a rationale for preemptive intervention, and define shared biological features of transplant-resistant MDS HSCs.
Open AccessPersistent Malignant Stem Cells Drive Relapse After Transplantation in the Myelodysplastic Neoplasms
The myelodysplastic neoplasms (MDS) are initiated in hematopoietic stem cells (HSCs). Allogeneic transplantation is the only curative treatment, but relapse remains common. To detect rare MDS HSCs, we developed an ultra-low-input DNA sequencing assay and applied it to a multicenter post-transplant cohort. HSC mutation detection preceded relapse by a mean of 98 days and strongly predicted relapse (95.7% vs. 30.3%; hazard ratio, 8.8; P=1.5e-7). Mutations detected only in unfractionated marrow did not predict relapse. We developed methods to measure donor-host HSC chimerism, improving relapse prediction sensitivity. Single-cell protein, DNA, and RNA analyses with mitochondrial lineage tracing confirmed MDS cell enrichment within immunophenotypically- and transcriptionally-defined HSCs, identifying shared ribosomal gene downregulation and candidate mechanisms of venetoclax sensitivity. Venetoclax/azacytidine depleted detectable MDS HSCs in longitudinally evaluated patients. These findings establish that HSC mutation detection predicts post-transplant relapse, provide a rationale for preemptive intervention, and define shared biological features of transplant-resistant MDS HSCs.
- 21 September 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- p. e014345
Clonal Hematopoiesis of Indeterminate Potential Proteomic Risk Score for Predicting Clinical Outcome in Patients With Heart Failure With Preserved Ejection Fraction
BACKGROUND: Clonal hematopoiesis of indeterminate potential (CHIP) is common in heart failure with preserved ejection fraction (HFpEF). However, the proteomic signatures linked to CHIP driver mutations and their prognostic implications in HFpEF remain poorly defined. We aimed to identify plasma protein signatures associated with CHIP driver mutations and to develop and externally validate a CHIP-proteomic risk score (CHIP-ProtRS) for predicting clinical outcomes in HFpEF. METHODS: The derivation cohort consisted of 118 TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) participants with available CHIP sequencing and proteomic profiling using the SomaScan platform. Associations between CHIP mutations and circulating proteins were assessed using gene-specific linear regression adjusted for age, with correction for multiple comparisons. Significant proteins were used to derive gene-specific proteomic classifiers using nested cross-validated least absolute shrinkage and selection operator logistic regression. A composite CHIP-ProtRS was generated using least absolute shrinkage and selection operator Cox regression and validated in a composite of 3 independent HFpEF cohorts (n=654). The primary end point was a composite of death and HF hospitalization. RESULTS: In TOPCAT, 30.5% of tested participants carried ≥1 CHIP mutation. Significant protein associations were identified for TET2 (7 proteins), DNMT3A (10), and PPM1D (5), all of which were enriched in immune and inflammatory pathways. Gene-specific least absolute shrinkage and selection operator models showed good discrimination for CHIP mutation (area under the curves, 0.752–0.898). The primary end point occurred in 28.0% of the derivation cohort and 34.7% of the validation cohorts. In the Cox-least absolute shrinkage and selection operator combination, only the TET2 -derived proteomic signature retained a nonzero coefficient in the CHIP-ProtRS. The CHIP-ProtRS was independently associated with the primary end point after adjustment for age, sex, Meta-Analysis Global Group in Chronic Heart Failure score, NT-proBNP (N-terminal pro-B-type natriuretic peptide), and atrial fibrillation in the derivation (adjusted hazard ratio, 1.42 [95% CI, 1.01–2.00]) and validation cohorts (adjusted hazard ratio, 1.16 [95% CI, 1.01–1.32]). CONCLUSIONS: CHIP is associated with alterations in plasma concentrations of immune/inflammatory proteins. A CHIP-ProtRS is independently associated with adverse outcomes in HFpEF, supporting its potential role as a biomarker of risk and underlying pathobiology.
- 21 September 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- p. e014345
Clonal Hematopoiesis of Indeterminate Potential Proteomic Risk Score for Predicting Clinical Outcome in Patients With Heart Failure With Preserved Ejection Fraction
BACKGROUND: Clonal hematopoiesis of indeterminate potential (CHIP) is common in heart failure with preserved ejection fraction (HFpEF). However, the proteomic signatures linked to CHIP driver mutations and their prognostic implications in HFpEF remain poorly defined. We aimed to identify plasma protein signatures associated with CHIP driver mutations and to develop and externally validate a CHIP-proteomic risk score (CHIP-ProtRS) for predicting clinical outcomes in HFpEF. METHODS: The derivation cohort consisted of 118 TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) participants with available CHIP sequencing and proteomic profiling using the SomaScan platform. Associations between CHIP mutations and circulating proteins were assessed using gene-specific linear regression adjusted for age, with correction for multiple comparisons. Significant proteins were used to derive gene-specific proteomic classifiers using nested cross-validated least absolute shrinkage and selection operator logistic regression. A composite CHIP-ProtRS was generated using least absolute shrinkage and selection operator Cox regression and validated in a composite of 3 independent HFpEF cohorts (n=654). The primary end point was a composite of death and HF hospitalization. RESULTS: In TOPCAT, 30.5% of tested participants carried ≥1 CHIP mutation. Significant protein associations were identified for TET2 (7 proteins), DNMT3A (10), and PPM1D (5), all of which were enriched in immune and inflammatory pathways. Gene-specific least absolute shrinkage and selection operator models showed good discrimination for CHIP mutation (area under the curves, 0.752–0.898). The primary end point occurred in 28.0% of the derivation cohort and 34.7% of the validation cohorts. In the Cox-least absolute shrinkage and selection operator combination, only the TET2 -derived proteomic signature retained a nonzero coefficient in the CHIP-ProtRS. The CHIP-ProtRS was independently associated with the primary end point after adjustment for age, sex, Meta-Analysis Global Group in Chronic Heart Failure score, NT-proBNP (N-terminal pro-B-type natriuretic peptide), and atrial fibrillation in the derivation (adjusted hazard ratio, 1.42 [95% CI, 1.01–2.00]) and validation cohorts (adjusted hazard ratio, 1.16 [95% CI, 1.01–1.32]). CONCLUSIONS: CHIP is associated with alterations in plasma concentrations of immune/inflammatory proteins. A CHIP-ProtRS is independently associated with adverse outcomes in HFpEF, supporting its potential role as a biomarker of risk and underlying pathobiology.
- Open Access
- 23 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8979
Polymorphic IGLV6-57 AL amyloid fibrils and features of a shared folding pathway
- 23 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8979
Open AccessPolymorphic IGLV6-57 AL amyloid fibrils and features of a shared folding pathway
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in Mice and Humans after Hematopoietic Cell Transplants
Supplementary Figure S7: Clinical variables associated with time to hematopoietic regeneration after allogeneic transplantation at Vanderbilt.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in Mice and Humans after Hematopoietic Cell Transplants
Supplementary Figure S7: Clinical variables associated with time to hematopoietic regeneration after allogeneic transplantation at Vanderbilt.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 9 from Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in Mice and Humans after Hematopoietic Cell Transplants
Supplementary Figure S9: The inhibitory effect of carvedilol on hematopoietic regeneration after syngeneic transplantation can be overcome by transplanting larger doses of bone marrow cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 9 from Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in Mice and Humans after Hematopoietic Cell Transplants
Supplementary Figure S9: The inhibitory effect of carvedilol on hematopoietic regeneration after syngeneic transplantation can be overcome by transplanting larger doses of bone marrow cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in Mice and Humans after Hematopoietic Cell Transplants
Supplementary Table S1. Characteristics of UTSW autologous transplant patients. Continuous measures are shown as mean (SD) and categorical measures as percentages. A one-way ANOVA was used to compare continuous variables, and a χ2 test was used to compare categorical measures.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in Mice and Humans after Hematopoietic Cell Transplants
Supplementary Table S1. Characteristics of UTSW autologous transplant patients. Continuous measures are shown as mean (SD) and categorical measures as percentages. A one-way ANOVA was used to compare continuous variables, and a χ2 test was used to compare categorical measures.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in Mice and Humans after Hematopoietic Cell Transplants
Supplementary Table S6. Related to Fig. 1-7. Key Resources Table.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in Mice and Humans after Hematopoietic Cell Transplants
Supplementary Table S6. Related to Fig. 1-7. Key Resources Table.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in Mice and Humans after Hematopoietic Cell Transplants
Supplementary Figure S8: Hematopoietic stem and progenitor cell frequencies after allogeneic transplantation.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in Mice and Humans after Hematopoietic Cell Transplants
Supplementary Figure S8: Hematopoietic stem and progenitor cell frequencies after allogeneic transplantation.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in Mice and Humans after Hematopoietic Cell Transplants
Supplementary Table S1. Characteristics of UTSW autologous transplant patients. Continuous measures are shown as mean (SD) and categorical measures as percentages. A one-way ANOVA was used to compare continuous variables, and a χ2 test was used to compare categorical measures.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in Mice and Humans after Hematopoietic Cell Transplants
Supplementary Table S1. Characteristics of UTSW autologous transplant patients. Continuous measures are shown as mean (SD) and categorical measures as percentages. A one-way ANOVA was used to compare continuous variables, and a χ2 test was used to compare categorical measures.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in Mice and Humans after Hematopoietic Cell Transplants
Supplementary Table S3. Characteristics of Vanderbilt autologous transplant patients. Continuous measures are shown as mean (SD), and categorical measures as percentages. A one-way ANOVA was used to compare continuous variables, and a χ2 test was used to compare categorical measures.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in Mice and Humans after Hematopoietic Cell Transplants
Supplementary Table S3. Characteristics of Vanderbilt autologous transplant patients. Continuous measures are shown as mean (SD), and categorical measures as percentages. A one-way ANOVA was used to compare continuous variables, and a χ2 test was used to compare categorical measures.